PorPsnctys

GYNECOLOGIC ONCOLOGY GROUP e HEADQUARTERS

OPERATIONS OFFICE 1234 MARKET STREET ® SUITE 430 ® PHILADELPHIA, PENNSYLVANIA 19107 © 215-928-6030
STATISTICAL OFFICE kress BUILDING — R.P.M.1. 666 ELM STREET ®BUFFALO, NEW YORK 14263 ® :

Fouret ELLER UN] VR

WY,
way S180”

a ere ae

      

aS

      
   
 

April 25, 1980 FF op oF THe PRESS

 

Joshua Lederberg, Ph.D.

Chairman

President of Rockefeller University
New York, New York 10021

Dear Dr. Lederberg:

In January, 1978, I wrote to the National Cancer Advisory Board Members indi-
vidually, calling to their attention the importance of the area of cooperative
clinical investigation for gynecologic cancer. The letter had been written
because the Gynecologic Oncology Group had had an unfavorable review by the
CCIRC with a resulting split vote relative to disapproval. Dr. Vincent DeVita
brought to the attention of the Board the entire situation that pertained to
the Gynecologic Oncology Group at that time. I do not need to repeat at

this time the information which I transmitted, but I assured the National
Cancer Advisory Board that the Gynecologic Oncology Group would definitely

do its best to bring itself up to the point where it would receive high ratings
as a result of its productive multi-discipline efforts. The Group has indeed
accomplished the objectives in meeting the requirements of the CCIRC and the
National Cancer Advisory Board.

A financial squeeze has occurred. The Gynecologic Oncology Group has received
an excellent rating only to find that there is no financial recognition for

its accomplishments in comparison with what other groups have received as they
progressed over the years. I am enclosing a copy of a letter I recently sent

to Dr. DeVita after his office and the Division of Cancer Treatment very kindly
arranged for Dr. John Macdonald to meet with representatives of the Gynecologic
Oncology Group on April 17, 1980. The letter with its attached enclosures is
being provided to you as a member of the National Cancer Advisory Board to bring
you up to date. It is intended to indicate to you that the Gynecologic Oncology
Group did fulfill the National Cancer Advisory Board's expectations and it will
continue to strive to do so. The letters also intended to indicate the current
financial improvement of the Gynecologic Oncology Group, so that the Board may
have this bit of evidence in its overall view of the relative priorities of
various programs coming under its jurisdiction. It is hoped that Dr. DeVita will
be able to resolve satisfactorily the many financial dilemmas that he faces with
your help, the support of Congress and many others who are devoted to the treat-

ment and prevention of cancer.
Singerely your t
ee UW fievedp bd
eorged®. Lewis, dr. A J

Group Chairman
GCL: rk

HEADQUARTERED AT DEPARTMENT OF OBSTETRICS AND GYNECOLOGY ® JEFFERSON MEDICAL COLLEGE